Revenio Group Oyj (HEL:REG1V)

Market Cap	423.02M -33.3%
Revenue (ttm)	111.05M +4.4%
Net Income	15.71M -17.7%
EPS	0.59 -17.7%
Shares Out	26.61M
PE Ratio	27.03
Forward PE	16.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,727
Open	16.22
Previous Close	16.28
Day's Range	15.78 - 16.40
52-Week Range	11.86 - 25.85
Beta	0.85
Analysts	Buy
Price Target	18.33 (+15.28%)
Earnings Date	Sep 8, 2026

About Revenio Group Oyj

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by vet...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 246
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: REG1V

Financial Performance

In 2025, Revenio Group Oyj's revenue was 109.85 million, an increase of 5.80% compared to the previous year's 103.82 million. Earnings were 17.41 million, a decrease of -5.87%.

Analyst Summary

According to 3 analysts, the average rating for REG1V stock is "Buy." The 12-month stock price target is €18.33, which is an increase of 15.28% from the latest price.

Price Target

€18.33

(15.28% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error